X hits on this document

119 views

0 shares

0 downloads

0 comments

31 / 61

Vasodilators in the Management of Acute Heart Failure Trial (VAMC)

Significant reduction in dyspnea score and PCWP with addition of NIseritide to standard therapy

Change in PCWP from baseline

Reduced dyspnea compared to standard therapy alone

Niseritide

Bolus 2 micr/kg

Nitroglycerine IV

489

Acute CHF

PCWP> 20mmHg

Randomized

Double-Blinded

Control

Effects at 3 hours

Outcomes

Primary End Point

Agents

Enrolled

Design

No good data to support adverse affects on renal function and niseritide

Retrospective analysis of VMAC showed potential for increased creatinin with increasing niseritide dose.

Document info
Document views119
Page views119
Page last viewedSun Dec 04 00:40:59 UTC 2016
Pages61
Paragraphs503
Words1542

Comments